JP2021535126A5 - - Google Patents
Info
- Publication number
- JP2021535126A5 JP2021535126A5 JP2021510174A JP2021510174A JP2021535126A5 JP 2021535126 A5 JP2021535126 A5 JP 2021535126A5 JP 2021510174 A JP2021510174 A JP 2021510174A JP 2021510174 A JP2021510174 A JP 2021510174A JP 2021535126 A5 JP2021535126 A5 JP 2021535126A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitors
- composition according
- pharmaceutically acceptable
- disease
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726172P | 2018-08-31 | 2018-08-31 | |
| US62/726,172 | 2018-08-31 | ||
| US201962883860P | 2019-08-07 | 2019-08-07 | |
| US62/883,860 | 2019-08-07 | ||
| PCT/IB2019/057259 WO2020044266A1 (en) | 2018-08-31 | 2019-08-28 | Combinations for treatment of nash/nafld and related diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021535126A JP2021535126A (ja) | 2021-12-16 |
| JP2021535126A5 true JP2021535126A5 (https=) | 2022-02-22 |
| JPWO2020044266A5 JPWO2020044266A5 (https=) | 2022-02-22 |
| JP7161605B2 JP7161605B2 (ja) | 2022-10-26 |
Family
ID=68165623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510174A Active JP7161605B2 (ja) | 2018-08-31 | 2019-08-28 | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11254660B2 (https=) |
| EP (1) | EP3843740A1 (https=) |
| JP (1) | JP7161605B2 (https=) |
| KR (1) | KR102614808B1 (https=) |
| CN (1) | CN112955147A (https=) |
| AU (1) | AU2019329884B2 (https=) |
| BR (1) | BR112021003039A2 (https=) |
| CA (1) | CA3110601C (https=) |
| CL (1) | CL2021000491A1 (https=) |
| CO (1) | CO2021002230A2 (https=) |
| CR (1) | CR20210110A (https=) |
| DO (1) | DOP2021000036A (https=) |
| EC (1) | ECSP21012501A (https=) |
| IL (1) | IL281093B2 (https=) |
| MA (1) | MA53496A (https=) |
| MX (1) | MX2021002428A (https=) |
| PH (1) | PH12021550339A1 (https=) |
| PY (1) | PY1972032A (https=) |
| SG (1) | SG11202101503RA (https=) |
| TW (1) | TWI718644B (https=) |
| UY (1) | UY38351A (https=) |
| WO (1) | WO2020044266A1 (https=) |
| ZA (1) | ZA202101090B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590161B2 (en) * | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| CR20210341A (es) * | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| EP3906022A1 (en) * | 2018-12-31 | 2021-11-10 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| CN115335055A (zh) * | 2020-03-11 | 2022-11-11 | 东亚St株式会社 | 用于预防或治疗非酒精性脂肪性肝炎的药物组合物 |
| WO2021211959A2 (en) * | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Methods and compositions for treating drug induced steatohepatitis |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| PE20231206A1 (es) * | 2020-08-21 | 2023-08-17 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112635049A (zh) * | 2020-12-23 | 2021-04-09 | 无锡市第二人民医院 | 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法 |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| US20250017938A1 (en) * | 2023-06-20 | 2025-01-16 | Sagimet Biosciences Inc. | Combination therapies of fasn inhibitors with thyroid hormone receptor agonists |
| WO2025080818A1 (en) * | 2023-10-10 | 2025-04-17 | Sagimet Biosciences Inc. | Combinations of fasn inhibitors and glp-1 agonists for liver diseases |
| CN118787746B (zh) * | 2024-07-01 | 2025-09-16 | 安徽省立医院(中国科学技术大学附属第一医院) | 脂肪酸合成酶抑制剂在预防及治疗药物性肝损伤中的应用 |
| CN120698959B (zh) * | 2025-05-29 | 2026-01-23 | 河北医科大学 | 一种达格列净-依折麦布共无定形物及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| KR100869616B1 (ko) | 2004-05-12 | 2008-11-21 | 화이자 프로덕츠 인코포레이티드 | 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도 |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| EA200900613A1 (ru) | 2006-11-29 | 2009-10-30 | Пфайзер Продактс Инк. | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
| MY151246A (en) | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| HRP20161178T1 (hr) * | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| SI3397631T1 (sl) * | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3713942T3 (fi) | 2017-11-21 | 2023-05-04 | Pfizer | 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola |
-
2019
- 2019-08-28 CR CR20210110A patent/CR20210110A/es unknown
- 2019-08-28 MA MA053496A patent/MA53496A/fr unknown
- 2019-08-28 US US16/553,818 patent/US11254660B2/en active Active
- 2019-08-28 CN CN201980071389.XA patent/CN112955147A/zh active Pending
- 2019-08-28 EP EP19783644.8A patent/EP3843740A1/en active Pending
- 2019-08-28 IL IL281093A patent/IL281093B2/en unknown
- 2019-08-28 BR BR112021003039-5A patent/BR112021003039A2/pt unknown
- 2019-08-28 AU AU2019329884A patent/AU2019329884B2/en active Active
- 2019-08-28 MX MX2021002428A patent/MX2021002428A/es unknown
- 2019-08-28 SG SG11202101503RA patent/SG11202101503RA/en unknown
- 2019-08-28 KR KR1020217009415A patent/KR102614808B1/ko active Active
- 2019-08-28 JP JP2021510174A patent/JP7161605B2/ja active Active
- 2019-08-28 WO PCT/IB2019/057259 patent/WO2020044266A1/en not_active Ceased
- 2019-08-28 CA CA3110601A patent/CA3110601C/en active Active
- 2019-08-28 TW TW108130771A patent/TWI718644B/zh active
- 2019-08-29 UY UY0001038351A patent/UY38351A/es not_active Application Discontinuation
- 2019-08-30 PY PY201901972032A patent/PY1972032A/es unknown
-
2021
- 2021-02-17 ZA ZA2021/01090A patent/ZA202101090B/en unknown
- 2021-02-17 PH PH12021550339A patent/PH12021550339A1/en unknown
- 2021-02-23 EC ECSENADI202112501A patent/ECSP21012501A/es unknown
- 2021-02-23 CO CONC2021/0002230A patent/CO2021002230A2/es unknown
- 2021-02-25 DO DO2021000036A patent/DOP2021000036A/es unknown
- 2021-02-26 CL CL2021000491A patent/CL2021000491A1/es unknown
- 2021-10-11 US US17/498,256 patent/US12247022B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535126A5 (https=) | ||
| JPWO2020044266A5 (https=) | ||
| JP2020200308A5 (https=) | ||
| US20080058339A1 (en) | New compounds | |
| US10017468B2 (en) | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | |
| JP6435323B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| US8962609B2 (en) | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | |
| JP5301456B2 (ja) | ヘテロアリールオキシキナゾリン誘導体 | |
| US10968193B2 (en) | Antidiabetic bicyclic compounds | |
| HRP20201748T1 (hr) | Inhibitori diacilglicerol-aciltransferaze | |
| TW202115086A (zh) | Bckdk抑制劑 | |
| JP6491656B2 (ja) | 新規アザベンズイミダゾール誘導体 | |
| JPWO2020261205A5 (https=) | ||
| US10603317B2 (en) | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | |
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| JP2019524831A5 (https=) | ||
| US10196381B2 (en) | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof | |
| CN107108525B (zh) | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 | |
| EA025859B1 (ru) | Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора | |
| US20120289497A1 (en) | Fused pyridine derivatives | |
| US20110160191A1 (en) | New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof | |
| MX2013003184A (es) | Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo. | |
| US12264139B2 (en) | Aryl sulfonamides as BLT1 antagonists | |
| TW201609644A (zh) | 吲哚酮衍生物、其製備及其治療用途 | |
| JPWO2009081782A1 (ja) | Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体 |